BAXBaxter International
Price
+3.0%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, no red flags, demanding price, growth steady, the market undecided.
Baxter International Inc., through our subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Baxter International (BAX) reported revenue of $2.96B in Q2 2026 (quarter ended Jun 30, 2026), up 5.3% from the same quarter a year earlier. That came with a gross margin of 35% and net income of $126M (4.3% of revenue). For the full year FY2025, revenue was $11.2B (+5.7% year on year) and net income −$957M. Its largest product in Q2 2026 was Infusion Therapies And Platforms at $769M, 50% of the disclosed total, well ahead of Care And Connectivity Solutions at 23%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 19, 2026Appointment of John Rogers as CFO On August 18, 2026, Baxter International Inc. (the “Company”) appointed John Rogers as Executive Vice President and Chief Financial Officer (“CFO”), effective as of October 1, 2026 (the “Transition Date”)Director or officer change · Form 8-K
- Aug 18, 2026Amendment to the Credit Agreement On August 18, 2026, Baxter International Inc. (the “Company”) entered into an amendment (“Amendment No. 2”) to the amended and restated five-year credit agreement dated June 11, 2025, among the Company, as Borrower Representative, Baxter Healthcare SA and Baxter World Trade SRL, as …Material agreement entered · Form 8-K
- Aug 4, 2026On August 4, 2026, Baxter International Inc. (the “Company”) issued a press release announcing the commencement of cash tender offers (each, an “Offer” and together, the “Offers”) to purchase up to $500 million in aggregate purchase price (excluding accrued and unpaid interest) of one or more series of the Company’s …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.54BThe company’s own SEC segment disclosure.
- Infusion Therapies And Platforms$769.0M50%
- Care And Connectivity Solutions$361.0M23%
- Front Line Care$226.0M15%
- Advanced Surgery$182.0M12%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
The closest names by size in the same industry